Afatinib, another FDA-approved EGFR inhibitor used against NSCLC, had anti-proliferative activity against all chordoma cell lines tested (IC50 < 0.7 μM) except for JHC720. This evidence concerns the gene EGFR and non-small cell lung carcinoma.